1	Clinical Performance of SARS-CoV-2 Rapid Antigen Tests: A Systematic
2	Review and Meta-Analysis
3	Nina Germic ^a , Johannes Hayer ^b and Qian Feng ^{a,*}
4	^a Roche Diagnostics International Ltd, Rotkreuz, Switzerland
5	^b Roche Diagnostics GmbH, Mannheim, Germany
6	
7	[*] Corresponding author:
8	Qian Feng
9	ADDRESS: Forrenstrasse 2, 6343 Rotkreuz, Switzerland
10	PH: +41 41 792 30 24
11	EMAIL: qian.feng.qf1@roche.com
12	
13	Other authors:
14	Nina Germic
15	EMAIL: nina.germic@roche.com
16	
17	Johannes Hayer
18	EMAIL: johannes.hayer@roche.com
19	
20	
21	

22 HIGHLIGHTS

23	•	Meta-analysis	of	86	studies	of	SARS-CoV-2	rapid	antigen	test	(RAT)
24		performance									

- RAT performance supports near-patient testing for early COVID-19 diagnosis
- RAT specificity is high and sensitivity is reliable in those with high viral load
- RAT sensitivity in symptomatic patients is higher than in asymptomatic individuals
- RAT sensitivity is higher for direct swabs compared to swabs in transport media

ABSTRACT

Objectives: We conducted a meta-analysis of RAT diagnostic accuracy for SARS-CoV-2 infections, and further evaluated test sensitivity versus the presence of symptoms, days post symptom onset (DPSO), sample viral load, and sample type (i.e. direct swabs versus specimens stored in transport media).

Methods: Three databases were searched systematically for performance evaluations of the Roche-distributed SDB SARS-CoV-2 Rapid Antigen Test (Roche/SDB RAT) through March 2022. If the Roche/SDB RAT was compared with any of 9 commonly available antigen tests, data from these tests were also included.

Results: Overall sensitivity of RATs among different manufacturers and study cohorts varied between 36.0% (95% CI: 24.0-50.1) and 79.4% (95% CI: 64.8-89.0). Roche/SDB RATs demonstrated a competitive performance with a pooled (including off-label use) sensitivity of 70.0%, and nearly 100% specificity in included studies. The Roche/SDB RATs exhibited reliable sensitivity in patients with a relatively high viral load (96.6% [95% CI: 95.2-98.2] for Ct≤25). Roche/SDB RATs were more sensitive in symptomatic patients within the first 7 DPSO (85.5% [95% CI: 81.2-88.4]), and when used to test direct swabs (74.4% [95% CI: 69.7-80.3]).

Conclusion: RATs show reliable performance in clinical settings and should be considered when rapid diagnosis of SARS-CoV-2 infection is critical.

Keywords: SARS-CoV-2, COVID-19, clinical performance, rapid antigen test, lateral

flow assay, point-of-care, in vitro diagnostics

31 INTRODUCTION

32 Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute 33 respiratory syndrome coronavirus 2 (SARS-CoV-2)[1] and as of August 2023, there 34 have been more than 769 million confirmed cases of COVID-19, including 6.9 million deaths reported to WHO.[2] The clinical spectrum of SARS-CoV-2 infection is wide, 35 36 ranging from an asymptomatic infection to severe pneumonia with acute respiratory 37 distress syndrome and death.[3-5] Timely diagnosis can contribute to clinical 38 management and outbreak control. Diagnostic testing involves detecting viral 39 biomarkers, or detecting the human immune response to the virus.[6] Commonly used diagnostic methods for SARS-CoV-2 include Real-Time Polymerase Chain Reaction 40 (RT-PCR), which has become the gold standard, viral culture, serology assays, and 41 antigen-detection tests, both at Point-of-Care and in laboratories.[7] RT-PCR enables 42 43 accurate diagnosis of SARS-CoV-2 infection with technical turn-around times ranging 44 from less than an hour to 24 hours.[8]

45 Rapid antigen tests (RATs) produce results quickly with a turnaround time of 15-30 minutes.[9] Further, RATs are convenient to use, widely available to the general 46 47 population, and less expensive than NAATs.[9] However, they are typically less sensitive than RT-PCR and other NAATs. Varying clinical performance has been 48 reported for SARS-CoV-2 RATs from different manufacturers and among diverse 49 50 patient populations on a global scale. A previous meta-analysis reported a pooled RAT sensitivity and specificity of 71.2% and 98.9% respectively, although sensitivity 51 increased to 76.3% when analysis was confined to studies that followed the 52 53 manufacturers' instructions.[10] A Cochrane review also summarized results from

54	various studies that examined or analyzed the diagnostic accuracy of rapid antigen
55	tests.[11] When tests were used according to manufacturer instructions, average
56	sensitivities by brand ranged from 34.3% to 91.3% in symptomatic participants for 20
57	tests with eligible data, while sensitivity ranged from 28.6% to 77.8% for 12 tests
58	studied in asymptomatic participants. Corman et al. showed that the Abbott Panbio™
59	COVID-19 Ag Rapid Test, the Healgen [®] Coronavirus Ag Rapid Test Cassette (Swab),
60	the R-Biopharm RIDA [®] QUICK SARS-CoV-2 Antigen Test, and the Roche/SD
61	Biosensor SARS-CoV-2 Rapid Antigen Test detect as few as 4-4 plaque-forming units
62	(PFU) of virus (88 PFU/mL).[12]
63	The SARS-CoV-2 Rapid Antigen Test manufactured by SD Biosensor and distributed
64	by Roche Diagnostics (equivalent to the STANDARD Q COVID-19 Ag Test; hereafter
65	"Roche/SDB RAT") ¹ was broadly used internationally during the pandemic, both in
66	professional point-of-care settings and as a self-test. To evaluate the diagnostic
67	accuracy of the Roche/SDB RAT, we performed an unbiased literature search
68	including studies across 36 different countries.[12] In this meta-analysis, we analyzed
69	the overall performance of the Roche/SDB RAT, followed by sub-analyses according to
70	the presence of symptoms, days post symptom onset (DPSO), cycle threshold (Ct)
71	ranges and sample types (direct swabs vs samples stored in transport media). If the
72	Roche/SDB RAT was compared with one of 9 other widely available antigen tests
73	(Abbott, Acon, BD, Biosynex, Boson, Laihe, MP BIO, Siemens, Quidel), data from
74	these tests were included as well.

¹ Also including SARS-CoV-2 Rapid Antigen Test Nasal and SARS-CoV-2 Antigen Self Test Nasal.

Our meta-analysis of 86 studies shows that RAT performance supports near-patient testing for early COVID-19 diagnosis, with reliable sensitivity in those with relatively high viral load. In general, RATs correctly diagnosed the bulk of SARS-CoV-2-infected persons within the first week of symptom onset.

79

80 OBJECTIVES AND STUDY DESIGN

81 Search Strategy

This meta-analysis was performed according to the Preferred Reporting Items for 82 83 Systematic Reviews and Meta-Analyses (PRISMA) guidelines.[13] SURUS, a custombuilt natural language processing (NLP) Engine (Medstone Science B.V.) was used to 84 conduct guery-based searches for relevant papers from January 2020 through March 85 2022. The databases MEDLINE, and preprint servers MedRixv and BioRxiv were 86 initially searched for clinical performance studies of a commercial SARS-CoV-2 RAT 87 with the following search strings: ("SARS-CoV-2" OR "Rapid antigen test" OR "point of 88 care" or "lateral flow assay" or "Roche/SD Biosensor/Standard Q") AND 89 ("nasopharyngeal" OR "nasal" OR "oro-nasopharyngeal" OR "oropharyngeal" OR "viral 90 culture") AND ("Sensitivity" OR "Specificity" OR "Accuracy" OR "PPA" OR "NPA" OR 91 "PPV" OR "NPV" OR "LOD" OR "TCID"). Only papers that evaluated the Roche/SDB 92 RAT performance with any of the specified parameters were considered if results were 93 reported at the manufacturer level. If the Roche/SDB RAT was compared with one of 94 the 9 other antigen tests of interest (Abbott, Acon, BD, Biosynex, Boson, Laihe, MP 95 96 BIO, Siemens, Quidel), the data from these tests were included as well.

In addition to the machine-learning approach, a manual search including FIND (The
Foundation for Innovative New Diagnostics [FIND], 2020) was conducted.

99 **Data Extraction**

Data extraction from identified studies was carried out by Medstone Science B.V. using 100 the NLP algorithm, and results were manually validated and verified. The following 101 102 information was extracted: publication characteristics (e.g., publication date, publication type, publication ID, and hyperlink to full text), study design (e.g., study size, location, 103 timelines, sample collection, reference test), characteristics of study participants (e.g., 104 age, presence of symptoms, DPSO at the time of diagnosis), test performance (e.g., 105 sensitivity and specificity) and QUADAS parameters for study quality.[14] We 106 considered 7 quality parameters that are known to affect test performance, including 1) 107 whether the patient sample represented the target population; 2) whether patient 108 selection criteria were clearly described; 3) whether the time interval between the 109 reference test and RAT was appropriately brief; 4) whether RAT execution was 110 described in sufficient detail for test replication; 5) whether reference test execution 111 was described in sufficient detail for test replication; 6) whether blinded interpretation of 112 RAT results occurred; and 7) whether patient withdrawals and sample exclusion were 113 explained. 114

115 Selection criteria

Initially, 135 records were identified. We excluded duplicates, records that were not in the English language or outside the analysis time window, and any publications that did

- not evaluate the Roche/SDB RAT, thus retaining 124 publications for further analysis.
- All 124 publications used an RT-PCR test as a comparator.
- 120 For qualitative analysis, studies were excluded if:
- a) the total number of analyzed samples was <100; or
- b) testing was not performed using clinical samples (i.e. contrived or cultured
 viral material); or
- 124 c) the specimen source for the antigen testing was only "saliva": or
- d) time between antigen sampling and comparator sampling was defined as ">
 24 hours".
- 127 Ninety-seven records were identified for qualitative analysis.

For quantitative analysis (meta-analysis), studies were excluded if no discernible numbers of true positive (TP) and false negative (FN), or true negative (TN) and false positive (FP) values could be manually extracted from the presented data in the eligible studies. Eighty-six records were identified for quantitative analysis.

132 Statistical Analysis

The extracted data were entered into an electronic database and classified according to the RAT that was studied. Information on the overall clinical performance (sensitivity, specificity) and stratified analysis based on DPSO, presence or absence of symptoms at the time of sampling, Ct values of paired RT-PCR results, and use of direct swabs vs specimens stored in transport media was recorded for each eligible study. As confidence intervals (CIs) reported in the publications were calculated using differing methods, all confidence intervals were recalculated using the exact Clopper– Pearson method for better comparability. Due to the heterogeneity in sub-groups and the small number of studies available for some RATs, we report the differences between tests descriptively rather than statistically. Relative sensitivity and specificity of RATs were calculated in relation to RT-PCR results as the gold standard (based on the number of TP, TN, FP, and FN values extracted from eligible studies).

The meta-analysis of the performance results of RATs against RT-PCR reference methods was performed using the statistical software R (R Foundation for Statistical Computing, 2020).

For overall clinical performance, we undertook the statistical pooling of estimates across all manufacturers namely Abbott, Acon, BD, Biosynex, Boson, Laihe, MP BIO, Roche, Siemens, and Quidel. The metaprop function from the "meta" package[15] was used to calculate the effect size for each individual test and pooled overall in a forest plot (**Figure 1**).

The stratified analyses discussed above are depicted as forest plots (**Figures 2 and 3**) which show the individual results of each study. Due to the high heterogeneity of the results in the different studies, rather than the mean, the median and a corresponding CI were used in the result descriptions. The CIs were calculated using a Wald interval on the ranks. In case the sample size was not sufficient for the calculations, the minimal and maximal study result per condition (and manufacturer) was used as a proxy for confidence limits. A bivariate model was fitted as a linear mixed model, and variance components were estimated by restricted maximum likelihood, using the reitsma function from the "mada" package[16, 17] for each system investigated in five or more studies.[18] The results are presented as a summary receiver operating characteristic (SROC) curve plot (**Figure 4**). The summary estimates, SROC curves, and confidence regions are depicted when a sufficient number of studies was available (>5 studies for SROC curves, >3 studies for summary estimates and confidence regions).

167

168 **RESULTS**

169 Per PRISMA guidelines, the selection of studies by applying the eligibility criteria is 170 summarized in Supplemental (Suppl.) Figure 1. According to our search criteria, 97 publications investigating 166,561 samples were included in this systematic review and 171 172 qualitative analysis. If the Roche/SDB RAT was compared with one of the 9 common 173 antigen tests of interest, the data from these tests were included as well. The search results included the following antigen tests of interest: i) Panbio[™] COVID-19 Ag Rapid 174 Test Device by Abbott (henceforth called "Abbott"); ii) Flowflex[®] SARS-CoV-2 Antigen 175 rapid test and COVID-19 Antigen Home Test by Acon Laboratories (henceforth called 176 "Acon"); iii) BD Veritor[™] System for Rapid Detection of SARS-CoV-2 by Becton 177 Dickinson (henceforth called "BD"); iv) BIOSYNEX COVID-19 Ag BSS by Biosynex SA 178 179 (henceforth called "Biosynex"); v) Rapid SARS-CoV-2 Antigen Test Card by Xiamen Boson Biotech (henceforth called "Boson"); vi) LYHER® Novel Coronavirus (COVID-180 19) Antigen Test Kit (Colloidal Gold) by Hangzhou Laihe Biotech (henceforth called 181 "Laihe"); vii) Rapid SARS-CoV-2 Antigen Test Card by MP Biomedicals (henceforth 182

called "MP Bio"); viii) CLINITEST[®] Rapid COVID-19 Antigen Test by Siemens
Healthineers (henceforth called "Siemens") and ix) Sofia SARS Antigen FIA by Quidel
Corporation (henceforth called "Quidel").

The Roche/SDB RAT was investigated in 36 countries within the selected time period. 186 We analyzed the number of studies investigating RAT performance by publication date 187 188 and geographical location (Figure 5). The number of identified studies increased 189 steadily through Q2 2021 as the pandemic progressed. Europe was the leading region evaluating Roche/SDB SARS-CoV-2 RAT performance (n= 65 records), with Asia a 190 191 distant second (n= 21 records). Studies published in 2021 reported higher numbers of participants compared to 2020, and this is likely due to the increased incidence of 192 SARS-CoV-2 as well as the broader acceptance and availability of RATs (Figure 5(b)). 193

Although the number of relevant studies may have reached a plateau, more participants were recruited in clinical trials in Q1 2022 (n=32,677) compared to Q1 2021 (n=10,380). In addition, the number of participants per quarter showed a trend of recruiting more participants per individual study.

198 **Overall sensitivity**

The quantitative analysis of overall sensitivities was performed for a subset of 84 studies, in which the exact TP and FN numbers were known. All studies included the Roche/SDB RAT (104 distinct cohorts), while Abbott was covered by 23 studies (24 cohorts), BD and Siemens by 7, Biosynex by 4, Acon by 3 studies, Boson was covered by 2 studies, and Laihe, MP Bio, and Quidel by 1 study. For these studies, the pooled sensitivity of RATs varied from 36.0% to 79.4% across manufacturers, with the pooled sensitivity for the Roche/SDB RAT of 70.0% (95% CI: 66.5-73.4) as shown in Figure
1(a) (also Suppl. Figure 2). Discrepancies and the wide range of RAT sensitivities
may have arisen due to several factors and sub-analyses for these parameters were
conducted to assess their impact on test performance.

209 Sensitivity in Symptomatic vs Asymptomatic Study Participants

210 The presence of COVID-19 symptoms (as reported by the studies) was used to perform a stratified sensitivity analysis as shown in Figure 2(a) (also Suppl. Figure 3). 211 Thirty-five studies included symptomatic subjects whereas 26 studies included 212 asymptomatic participants. The median sensitivity of RATs in symptomatic patients 213 was considerably higher (78.0% [95% CI: 73.3-82.7]) than in those without symptoms 214 (49.6% [95% CI: 38.6-58.7]), suggesting that RATs are more effective in detecting an 215 infection in the symptomatic population. This is consistent with previous studies 216 reporting higher RAT sensitivity in the symptomatic population.[19, 20] 217

The Roche/SDB RAT demonstrated a median sensitivity of 78.9% [95% CI: 74.4-83.4] in symptomatic patients (n=43 distinct cohorts from 35 studies), and a median sensitivity of 53.3% [95% CI: 43.6-63.0] in asymptomatic subjects (n=27 distinct cohorts from 26 studies). Thirteen studies² included RATs from other manufacturers, and reported median sensitivity between 68.6% - 90.4% in symptomatic cohorts and between 27.3% - 57.3% in asymptomatic cohorts.

224 Sensitivity for Days Post Symptom Onset (DPSO)

² These 13 studies included the following subsets: 12 studies for sensitivity in symptomatic patients, and 7 studies for sensitivity in asymptomatic patients,.

Time elapsed since symptom onset is a clinically relevant parameter.[9, 21-23] Therefore, we analyzed the performance of RATs with regard to DPSO in symptomatic populations. The results showed the following median sensitivity of RATs overall: 85.9% [95% CI: 79.2-92.3], 86.1% [95% CI: 81.2-88.2] and 50.0% [95% CI: 38.2-62.5] for \leq 5, \leq 7 and >7 DPSO, respectively (**Figure 2(b), also Suppl. Figure 4**).

The Roche/SDB RAT showed a very similar median sensitivity profile of 86.0% [95% CI: 79.2-92.9], 85.5% [95% CI: 81.2-88.4] and 57.1% [95% CI: 38.2-66.7] for $\leq 5, \leq 7$ and >7 DPSO, respectively.

233 Sensitivity by Cycle Threshold (Ct)

RAT performance is commonly expressed as relative sensitivity and specificity against RT-PCR. All included studies used Cycle Threshold (Ct) values of the RT-PCR methods as a proxy for viral load in samples, likely due to the lack of an internationally standardized quantitative method at the time these studies were conducted.

Pooled sensitivities grouped by Ct thresholds for each manufacturer as shown in the 238 forest plot in Figure 3(a) ranged from 42.5% to 100% (also Suppl. Figure 5). The 239 240 median sensitivities of the Roche/SDB RAT for Ct values of ≤20, ≤25 and ≤30 were 100.0% [95% CI: 97.2-100], 96.6% [95% CI: 95.2-98.2] and 85.3% [95% CI: 83.3-88.6], 241 respectively. These results showed that RATs are well suited to detect infected 242 individuals with relatively high viral loads, which have been associated with higher risk 243 of virus transmission.[24, 25] Higher Ct values were generally associated with reduced 244 sensitivities. 245

246 Sensitivity for Direct Swabs vs Samples Stored in Transport Media

The majority of SARS-CoV-2 RATs support performance claims for direct swabs from the upper respiratory tract, which must be eluted in the proprietary buffer supplied by the manufacturer. For some RATs, swabs eluted in specific transport media are also validated and claimed. However, due to practical and usability reasons swab samples eluted in a variety of transport media were often used to validate RAT performance in clinical studies and practice.

Our results show slightly inferior median sensitivity for samples eluted/stored in transport media (63.9% [95% CI: 54.0-70.0]) versus direct swabs (72.0% [95% CI: 68.6-76.6]) across manufacturers, although most of the contributing studies were of the Roche/SDB RAT, as shown in **Figure 3(b).** The median sensitivity of the Roche/SDB RAT for direct swabs and for samples stored in transport media is 74.4% [95% CI: 69.7-80.3] (61 distinct cohorts from 46 studies) and 66.5% [95% CI: 50.9-72.5] (37 distinct cohorts from 33 studies) respectively.

260 **Overall Specificity**

RATs generally have high specificity. This is also reflected in our meta-analysis. The 261 pooled specificity for all manufacturers ranged from 99.1% to 100%, with the pooled 262 263 specificity for the Roche/SDB RAT of 99.5% [95% CI: 99.3-99.7] as shown in Figure 1(b) (also Suppl. Figure 6). The presence or absence of symptoms had little effect on 264 RAT median specificity (99.8% [95% CI: 99.4-100] or (99.8% [95% CI: 99.6-100]), 265 respectively). Also, the use of transport media did not influence RAT specificity when 266 compared to direct swabs. Our meta-analysis showed equivalent specificity for direct 267 swabs and samples stored in transport media (99.6% and 99.8% respectively) across 268 269 different manufacturers, although most of the contributing studies were of the

Roche/SDB RAT (99.6% [95% CI: 99.3-99.7] and 99.7% [95% CI: 97.7-100]
respectively) as depicted in Suppl. Figure 7.

272 SROC Analyses for all RATs

SROC plots are cumulative ROC plots for data derived from multiple studies that can 273 depict both sensitivity and specificity; for a meaningful analysis a certain sample size is 274 275 needed. An SROC curve was included only for RATs assessed in more than 5 cohorts, and the overall model estimate per manufacturer with corresponding confidence ellipse 276 only for RATs assessed in more than 3 cohorts. As shown in Figure 4, the 277 278 Roche/SDB, BD and Abbott RATs showed similar performance with largely overlapping Cls while the performance of the Siemens RAT was slightly inferior based on this 279 limited data set (n = 5 studies). 280

281

282 **DISCUSSION**

283 RATs played a critical role during the COVID-19 pandemic. Comprehensive 284 understanding of the capabilities and limitations of RATs for SARS-CoV-2 diagnosis is 285 crucial to assess their utility in an endemic setting. It is important to note that RATs have been shown to be sensitive enough to detect cases with relatively high viral 286 loads, i.e. pre-symptomatic and early symptomatic cases, [26-28] with a slight 287 advantage for direct swabs versus samples stored in transport media.[29] Such cases 288 are likely to account for a significant proportion of transmissions.[24] At present the 289 290 World Health Organization recommends that RATs meet the minimum performance requirement of at least 80% sensitivity and 97% specificity when compared to NAATs 291

for SARS-CoV-2 detection in symptomatic individuals within the first 7 days of
symptoms onset.[23] The US Centers for Disease Control and Prevention (CDC), the
European Center for Disease Prevention and Control (eCDC) and the European Union
(EU) also set similar requirements for specific cohorts based on symptoms and DPSO,
and recommend comparing the RAT results to well characterized and highly sensitive
RT-PCR methods.[9, 21, 22]

298 This global systematic review and meta-analysis presents an overview of the key confounders across studies that report the sensitivity and specificity of commercially 299 300 available SARS-CoV-2 RATs. Altogether, 97 articles investigating the use of RATs from 10 different manufacturers across 166,561 samples presented findings based on 301 Ct and DPSO ranges, for direct swabs versus samples stored in transport media, and 302 for symptomatic versus asymptomatic patients. The performance of RATs was 303 calculated as relative sensitivity and specificity against RT-PCR results. RATs were 304 305 typically more sensitive for symptomatic patients, when used less than 7 days after symptom onset, and when using direct swabs. Particularly in samples with a relatively 306 307 high viral load, which has been associated with increased transmission probability, [24] 308 RATs demonstrated convincing and reliable sensitivity. RAT specificity was generally very high and independent of the parameters assessed in this meta-analysis. The 309 310 Roche/SDB RAT performed competitively based on the studies assessed, and we found significant differences in test performance across RATs in various studies, 311 312 though the sample size for some RATs was very small.

We did not aim to assess statistical significance, but the multiple trials selected for systematic review and meta-analysis have a widespread distribution covering a range

of prevalence and patient populations, thus the results are generalizable on a larger
 scale. Overall the results support the applicability of RATs for early case detection.

317 This study has some limitations. The variation in test sensitivity observed across 318 studies may have been caused by the heterogeneity of study populations, with different disease severity levels and sampling at different time points. The use of different 319 320 sample types, extraction methods and RT-PCR reference tests may also have 321 contributed to this variation. Further, our meta-analysis focused on studies evaluating the Roche/SDB RAT, and only included a small number of studies that compared the 322 323 Roche/SDB RAT against a selection of tests offered by other manufacturers. Finally, the meta-analysis contains a limited number of studies that tested the Omicron variant 324 of SARS-CoV-2 due to the timing of this search. Assessment of later studies conducted 325 during the Omicron wave is needed to gain greater insight into RAT diagnostic 326 327 accuracy in this context, although few novel mutations have been identified in the Omicron nucleocapsid protein (target of most RATs) compared to earlier variants.[7] 328

In conclusion, the diagnostic accuracy of the SARS-CoV-2 Roche/SDB rapid antigen test in detecting SARS-CoV-2 infections was robust and reliable, especially in samples with a relatively high viral load. Based on 86 studies including comparisons to other RATs, the Roche/SDB RAT showed competitive performance. These results support the use of RATs for early detection of infections and identification of individuals with significant viral loads, thereby contributing to patient management as well as transmission-control decision making.



337



Figure 1. (a) Forest plot of included studies showing overall sensitivity across different RATs. Each row corresponds to one study (if distinct cohorts were presented within one study, the sensitivity is presented

339

- 343 per cohort). Sensitivity is marked by a dot and the corresponding 95% confidence interval by a line, with
- 344 the results ordered by test manufacturer. Additionally, the summary result for each manufacturer is
- 345 depicted by a diamond at the end of each section. (b) Forest plot of studies evaluating overall specificity
- 346 across RAT manufacturers.







- 353 Figure 2: (a) Forest plot of studies showing sensitivity for symptomatic and asymptomatic patients,
- 354 grouped by RAT manufacturer. (b) Forest plot of studies showing sensitivity grouped by Days Post
- 355 Symptom Onset (DPSO) threshold (≤ 5 , ≤ 7 and >7).







(b)



Figure 3: (a) Forest plot of studies showing sensitivity across the cycle (Ct) threshold range grouped by

369 Ct thresholds (≤ 20 , ≤ 25 , ≤ 30 and ≤ 33). (b) Forest plot of studies showing sensitivity for direct swabs

370 versus samples stored in transport media, grouped by RAT manufacturer. (c) Histogram of sensitivities

371 for direct swabs versus samples stored in transport media.

372



374

375

Figure 4: SROC plots for all RATs across different manufacturers. The summary estimate is shown as a filled marker and the associated 95% confidence ellipse as thin dashed lines for each RAT that was covered in more than 3 studies. The SROC curve (thick solid lines) was plotted for all RATs that were covered by more than 5 studies.

380

381

382

383





386



388 geographical location. (a) Distribution of included studies temporally and regionally (b) Distribution of the

included study participants temporally and regionally. (c) Distribution of included studies temporally by

390 RAT manufacturer. (d) Distribution of included study participants temporally by RAT manufacturer.

- 392 Acknowledgements: The authors would like to acknowledge the contribution of Sumedha Sinha
- 393 (Roche Diagnostics Solutions, Pleasanton, California, USA) for writing assistance and proofreading of
- the article.
- **Funding:** This work was supported by Roche Diagnostics International Ltd.
- 396 Declaration of Competing Interest: NG and QF are employees of Roche Diagnostics International Ltd
- and JH is an employee of Roche Diagnostics GmbH. QF holds stocks in F. Hoffmann-La Roche Ltd.
- 398 Ethical Approval: The data supporting this manuscript are from published studies, each reporting their
- 399 own IRB approvals.
- 400 **Disclaimer**: The Roche/SD Biosensor SARS-CoV-2 Rapid Antigen Test/SARS-CoV-2 Rapid Antigen
- 401 Test Nasal/ SARS-CoV-2 Antigen Self Test Nasal (Roche/SDB RAT) is an in vitro diagnostic test in
- 402 countries accepting the CE mark.
- 403

405 APPENDIX 1 - Supplemental Figures

406 FIGURES



407

- 408 Supplemental Figure 1: PRISMA Flow chart of study selection for inclusion in the meta-analysis and
- 409 systematic review.

Study		Study	
Manufacturer = Abbott		Manufacturer = SDB/Roche (cont'd)	
Baro et al. (2021)		Fourati et al. (2021)	
Sitoe et al. (2022)		Homza et al. (2021)	
aruana et al. (2021)		Koeleman et al. (2021)	
Diearo et al. (2020)		Schuit et al. (2021)	
lóra et al. (2022)	-8-	Abdul-Mumin et al. (2021)	
hommes et al. (2021)		Nóra et al. (2022)	- 0
leewandara et al. (2022)		Jegerlehner et al. (2021)	
Peto (2021)	- 2	Pérez-García et al. (2021)	
Venekamp et al. (2021)		Labhardt et al. (2022)	
Fourati et al. (2021)	-2-	Park et al. (2022)	
Wertenauer et al. (2022)		Kawser et al. (2021)	
Pérez-García et al. (2021)	-0-	Holzner et al. (2021)	-22-
Pilecky et al. (2022)		Paap et al. (2021)	- 2-
Scheiblauer et al. (2021)		Jakobsen et al. (2021)	
Favresse et al (2021)		Favresse et al (2021)	-8-
Venekamp et al. (2021)		Peña et al. (2021)	
Koeleman et al. (2021)		Nalumansi et al. (2020)	
Navero-Castillejos et al. (2022)	-9_	Labhardt et al. (2022)	-0
Van Honacker et al. (2021) Validation		Ceruti et al. (2021)	
HSE COVID19 Antigen Testing Working Group (2021)		Kruttgen et al. (2021)	
Jaaskelainen et al. (2021)		FIND (2021)	-9-
Ronstantinus et al. (2021)		Fernandez-Montero et al. (2021)	
Berger et al. (2021) Sobwob. et al. (2020)		Mockel et al. (2021)	-
Scriwob et al. (2020)		Salvagno et al. (2020)	
Random effects model	\sim	Osterman et al. (2021)	
received on the second se		FIND (2021)	
Janufacturer - Slemens		FIND (2021) Navero Castilleios et al. (0000)	
Dilecky et al. (2022)		lindher et al. (2021)	
Nóra et al (2022)		Venekamp et al. (2021)	
Baro et al. (2022)		Venekamp et al. (2021)	-0-
Diearo et al. (2020)		Mori et al. (2021)	
Bavart et al (2022)	-	Mockeletal (2021)	
Scheiblauer et al. (2021)		Petia- Bodriguez et al. (2021)	
Navero-Castilleios et al. (2022)		FIND (2020)	
Random effects model	\sim	Kruger et al. (2020)	
Heterogeneity: $l^2 = 85\%$, $\tau^2 = 0.2881$, $\rho < 0.01$		Lee et al. (2022)	- 2
		Begum et al. (2021)	
Manufacturer = BD		Igloi et al. (2021)	-
Scheiblauer et al. (2021)		Lindner et al. (2021)	
Caruana et al. (2021)		Thell et al. (2021)	- 2
Stohr et al 2021	-8-	FIND (2021)	
Schuit et al. (2021)	-8-	Jaaskelainen et al. (2021)	-0
Venekamp et al. (2021)		Lee et al. (2022)	
Koeleman et al. (2021)		Gupta et al. (2020)	
kawser et al. (2021)		Kruger et al. (2021)	-0
Random effects model		Lindner et al. (2021)	
Heterogeneity: $I^{c} = 89\%$, $\tau^{c} = 0.4150$, $\rho < 0.01$		Van Honacker et al. (2021) validation	-
Manufacturer, MD Dia		Turcato et al. (2021)	-2
Manufacturer = MP BIO	-	FIND (2021)	
scheiblauer et al. (2021)		FIND (2021)	_
Janufacturer - Placyney		Finck et al. (2021)	
Fourati et al. (2021)	-	Degum et al. (2021)	_
Foundinen at al. (2021)	-	Igiol et al. (2021)	-
Scheibiduer et di. (2021) HSE COVID19 Antigen Testing Working Crown (2001)		Lindher et al. (2021)	
ASE COVID19 Antigen Testing Working Group (2021)		Hanman et al. (2021)	-
Random effects model		Nikolai et al. (2021)	
Haterogeneity $l^2 = 0.007$ $p < 0.01$		Nikolal et al. (2021)	
neterogeneity, $r = 00.\%$, $t = 0.430r$, $p < 0.01$		HSE COVID19 Antigen resulting working Group (2021) Revert et al. (2022)	
Manufacturer - SDR/Roche		Konstantinus et al. (2022)	
Oh et al. (2021)			
Osterman et al (2021)		FIND (2020)	
Caruana et al. (2021)		Render et al. (2021)	
ee et al. (2021)		Kim et al. (2021)	
Alghounaim et al. (2021)		Anarwal et al. (2021)	
leewandara et al. (2022)	_	Nikolai et al. (2021)	
	-	Nikolai et al. (2001)	
opera et al. (2021)		NIKUIAI ELAI. (2021)	
opera et al. (2021) Caruana et al. (2021)	-8-	Ahnen et al 2021	
opera et al. (2021) Caruana et al. (2021) Korenkov et al (2021)	0 0 0	Ahnen et al (2021) Schwob et al (2020)	
opera et al. (2021) Jaruana et al. (2021) Korenkov et al (2021) Sohmer et al. (2021)		Ahnen et al (2021) Schwob et al. (2020) Chaimavo et al. (2020)	
opera et al. (2021) caruana et al. (2021) corenkov et al. (2021) cohmer et al. (2021) saro et al. (2021)	0 0 0 0	Ahnen et al 2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model	\$
opera et al. (2021) aruana et al. (2021) corenkov et al. (2021) cohmer et al. (2021) baro et al. (2021) tioe et al. (2022)	- 2 - - 2 - - 2 - - 2 - - 2 - - 2 - - 2 -	Ahnen et al 2021 Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heleropenetty: $\vec{f} = 93\%, \vec{s}^2 = 0.6453, n < 0.01$	\$
opera et al. (2021) aruana et al. (2021) otorenkov et al (2021) otomer et al. (2021) aro et al. (2021) äitoe et al. (2022) Scheiblauer et al. (2021)	- 0 - 0 - 0 - 0 - 0 - 0 - 0	Almona et al. (2021) Almen et al 2021 Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{r} = 93\%$, $\vec{r}^2 = 0.6453$, $p < 0.01$	\$
opera et al. (2021) Caruana et al. (2021) Cornekov et al. (2021) Cohmer et al. (2021) Saro et al. (2021) Sitoe et al. (2022) Scheiblauer et al. (2021) Seterman et al. (2021)	- 8 - - 9 - - 8 - - 8 - - 8 - - 8 - - 8 - - 8 -	Althone et al (2021) Althone et al (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $P = 93\%$, $T = 0.6453$, $p < 0.01$ Manufacturer = Acop	\$
opera et al. (2021) caruana et al. (2021) corenkov et al. (2021) corenkov et al. (2021) Baro et al. (2021) Baro et al. (2022) Scheiblauer et al. (2021) Disterman et al. (2021) Evolo (2021)	-8- -9- -9- -9- -9- -9- -9- -9- -9- -9-	Ahnen et al (2021) Ahnen et al (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity. P = 93%, 2 = 0.6453, p < 0.01 Manufacturer = Acon Pilecky et al. (2022)	⇒
opera et al. (2021) Saruana et al. (2021) Sofmerkov et al. (2021) Sofmer et al. (2021) Saro et al. (2021) Sitoe et al. (2021) Sotenbiauer et al. (2021) Disterman et al. (2021) Peto (2021) Mungomklang et al. (2021)	- 8	Almona et al. (2021) Almen et al 2021 Schwob et al. (2020) Chaimayo et al. (2020) Random effecta model Heterogeneity: $P^2 = 93\%$, $r^2 = 0.6453$, $p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021)	 → →
opera et al. (2021) Caruana et al. (2021) Comenco et al. (2021) Soroneto at. (2021) Sito et al. (2021) Sito et al. (2022) Scheiblauer et al. (2021) Seterman et al. (2021) Veto (2021) Veto (2021) Autopomkiang et al. (2021) akobsen et al (2021)	- 8 - - 8 -	Almona et al (2021) Almen et al 2021 Schwob et al. (2020) Random effects model Heterogeneity: $P = 93\%$, $r^2 = 0.6453$, $p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022)	~ - 0 - 0
opera et al. (2021) Saruana et al. (2021) Korenkov et al (2021) Sohmer et al. (2021) Sitoe et al. (2021) Sitoe et al. (2021) Soheiblauer et al. (2021) Seterman et al. (2021) Peto (2021) MungornKlang et al. (2021) Jakobsen et al (2021) Jakobsen et al (2021)	- 8 - - 8 -	Annone et al (2021) Annen et al (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effecta model Heterogeneity: $P = 93\%, r^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pileoky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model	⇒ -0
opera et al. (2021) Caruana et al. (2021) Corenkov et al. (2021) Cohmer et al. (2021) Saro et al. (2021) Saro et al. (2021) Sator et al. (2021) Saterman et al. (2021) Saterman et al. (2021) Vangomklang et al. (2021) Iakobsen et al (2020) Jeano et al. (2020) Jeano et al. (2021)	- 8 - 9 - 9	Alineme et al (2021) Alineme et al (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{r} = 93\%, \tau^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{r} = 94\%, \tau^2 = 0.4650, p < 0.01$	- 0
opera et al. (2021) Caruana et al. (2021) Cornekov et al. (2021) Sornekov et al. (2021) Saro et al. (2021) Sibce et al. (2022) Scheiblauer et al. (2021) Seterman et al. (2021) Peto (2021) Mungomklang et al. (2021) Alaxobsen et al. (2021) Diearo et al. (2022) Paap et al. (2022)	- 8 - - 9 - - 9 - - 8 - - 8 - - 8 - - 8 - - 8 - - 8 - - 9 - - 9 - - 9 - - 9 - - 9 -	Almona et al. (2021) Almen et al (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity. $\vec{P} = 93\%, \vec{r}^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity. $\vec{P} = 94\%, \vec{r}^2 = 0.4650, p < 0.01$	⇒ -00
opera et al. (2021) Saruana et al. (2021) Sorienkov et al. (2021) Sorienkov et al. (2021) Saro et al. (2021) Sitoe et al. (2021) Sitoeren et al. (2021) Siterman et al. (2021) Siterman et al. (2021) Siterna et al. (2021) Bearo et al. (2020) Paap et al. (2022) Mandey et al. (2021)	- 8 - - 9 -	Alineme et al (2021) Alineme et al (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{P} = 93\%, \vec{r}^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 94\%, \vec{r}^2 = 0.4650, p < 0.01$ Manufacturer = Boson	⇒ -0 -0
opera et al. (2021) Caruana et al. (2021) Corenkov et al. (2021) Cohmer et al. (2021) Sitore et al. (2021) Sitore et al. (2021) Siterman et al. (2021) Siterman et al. (2021) Veto (2021) Mungomklang et al. (2021) Jeano et al. (2020) Paap et al. (2021) Piecky et al. (2021) Piecky et al. (2021) Sitore et al. (2021) S		Almona et al. (2021) Almen et al (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{r} = 93\%, \vec{r}^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{r} = 94\%, \vec{r}^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021)	~
opera et al. (2021) aruana et al. (2021) corenkov et al. (2021) corenkov et al. (2021) aruo et al. (2021) aro et al. (2021) titoe et al. (2021) breinebiauer et al. (2021) breinebiauer et al. (2021) breinebiauer et al. (2021) akobsen et al. (2021) akobsen et al. (2021) arabe et al. (2021) tilecky et al. (2022) andey et al. (2021) IND (2021) an Honacker et al. (2021) implementation		Ahnen et al (2021) Ahnen et al (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effecta model Heterogeneity: $P = 93\%, P = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022)	⇒
opera et al. (2021) caruana et al. (2021) corenkov et al. (2021) corenkov et al. (2021) store et al. (2021) store et al. (2021) store et al. (2021) sterman et al. (2021) sterman et al. (2021) akobsen et al. (2021) an Honacker et al. (2021) implementation torist et al. (2022)		Alinoia et al. (2021) Alinen et al 2021 Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{r} = 93\%, \vec{r}^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{r} = 94\%, \vec{r}^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model	
opera et al. (2021) arunan et al. (2021) Korenkov et.al (2021) Korenkov et.al (2021) Sone et al. (2021) Sitoe et al. (2021) Sitoe et al. (2021) Soterbibauer et al. (2021) Soterbibauer et al. (2021) Peto (2021) MungomKlang et al. (2021) Beano et al. (2022) Pandey et al. (2021) Pandey et al. (2021) Pandey et al. (2021) Pandey et al. (2022) Pandey et al. (2021) Pandey et al. (2022) Pandey et al. (2021) Pandey et al. (2022) Pandey et al. (2021) Pandey et al. (2021) Pandey et al. (2021) Pandey et al. (2022) Pandey et al. (2022) Pandey et al. (2021) Pandey et al. (202		Annota et al. (2021) Annone et al. (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $P = 93\%, r^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $P = 94\%, r^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $P = 95\%, r^2 = 0.233, p < 0.01$	 → →
opera et al. (2021) Saruana et al. (2021) Sorienkov et al (2021) Sorienkov et al. (2021) Sorienko et al. (2021) Sitoe et al. (2021) Sitoeren et al. (2021) Siterman et al. (2021) Siterman et al. (2021) Siterna et al. (202		Alinea et al. (2021) Alinea et al. (2021) Softwole et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{P} = 93\%, \vec{r}^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 94\%, \vec{r}^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 89\%, \vec{r}^2 = 0.2303, p < 0.01$	-0-
opera et al. (2021) caruana et al. (2021) corenkov et al. (2021) corenkov et al. (2021) store et al. (2021) store et al. (2021) store et al. (2021) sterman et al. (2021) veto (2021) fungomklang et al. (2021) akobsen et al. (2021) akobsen et al. (2021) akobsen et al. (2021) akobsen et al. (2021) veto (2021) veto (2021) veto (2021) veto (2021) veto (2021) veto (2021) veto (2021) veto (2021) constantinue et al. (2021) o et al. (2021) o et al. (2021)		Almona et al. (2021) Almen et al. (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{P} = 93\%, \vec{r}^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 94\%, \vec{r}^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 99\%, \vec{r}^2 = 0.2303, p < 0.01$	 → →
opera et al. (2021) Saruana et al. (2021) Sorienkov et al. (2021) Sorienkov et al. (2021) Sorienkov et al. (2021) Sitoe et al. (2021) Soriebibiauer et al. (2021) Soriebibiauer et al. (2021) Soriebibiauer et al. (2021) Soriebibiauer et al. (2021) Bearo et al. (2020) Vaap et al. (2020) Vaap et al. (2021) NIND (2021) Kin Honacker et al. (2021) Soriantinus et al. (2021) Soriantinus et al. (2021) Voopalasingam et al. (2022) Soriantinus et al. (2021) Soriantinus		Animola et al. (2021) Anima et al. (2021) Softwole et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{P} = 93\%, \vec{x}^2 = 0.6453, p < 0.01$ Manufacturer = Acon Piliceky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 94\%, \vec{x}^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 89\%, \vec{x}^2 = 0.2303, p < 0.01$ Manufacturer = Lyher Scheiblauer et al. (2021)	-
opera et al. (2021) Caruana et al. (2021) Sornekov et al (2021) Sornekov et al (2021) Sorneko et al. (2021) Sitore et al. (2021) Sitore et al. (2021) Siterman et al. (2021) Seterman et al. (2021) Setor (2021) Mungomklang et al. (2021) Iakobsen et al (2021) Sapa et al. (2021) Sitore et al. (2021) Sitore et al. (2021) Sortist et al. (2022) Constantinus et al. (2021) o et al. (2021) Sortist et al. (2022) Constantinus et al. (2021) Sortist et al. (2022) Sortist et al. (2021) Sortist et al. (2022) Sortist et al. (2021) Sortist		Almoda et al. (2021) Almen et al 2021 Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $P = 93\%, r^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $P = 94\%, r^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $P = 99\%, r^2 = 0.2303, p < 0.01$ Manufacturer = Lyher Scheiblauer et al. (2021)	~
opera et al. (2021) Saruana et al. (2021) Sorenkov et al (2021) Sorenkov et al. (2021) Sorenkov et al. (2021) Sitoe et al. (2021) Sitoe et al. (2021) Sterman et al. (2021) Veto (2021) Mungomklang et al. (2021) Searo et al. (2021) Veto (2022) Vangomklang et al. (2021) Veto (2022) Vandey et al. (2022) Vilecky et al. (2022) Vinto (2021) Kan Honacker et al. (2021) o et al. (2021) o et al. (2021) o et al. (2021) Sonstantinus et al. (2022) Voopalasingam et al. (2021) Voopalasingam et al.		Ahnon et al. (2021) Ahnon et al. (2021) Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $P = 93\%, r^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $P = 94\%, r^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $P = 89\%, r^2 = 0.2303, p < 0.01$ Manufacturer = Lyher Scheiblauer et al. (2021)	
opera et al. (2021) Saruana et al. (2021) Sofenkov et al (2021) Sofenkov et al (2021) Sofenka et al. (2021) Sifue et al. (2021) Sifuera et al. (2021) Siferman et al. (2021) Soferman et al. (2021) Soferman et al. (2021) Soferman et al. (2021) Soferman et al. (2022) Siferman et al. (2021) Siferman et al. (2021) Siferman et al. (2021) Siferman et al. (2022) Siferman et al. (2021) Siferman et al. (2022) Siferman et al. (2022) Siferman et al. (2021) Siferman et al. (Almona et al. (2021) Almen et al. (2021) Softwole et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{P} = 93\%, \vec{X} = 0.6453, p < 0.01$ Manufacturer = Acon Pileoky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 94\%, \vec{X} = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{P} = 89\%, \vec{X} = 0.2303, p < 0.01$ Manufacturer = Lyher Scheiblauer et al. (2021) Manufacturer = Cuidel Scheiblauer et al. (2021)	
Lopera et al. (2021) Caruana et al. (2021) Sornekov et al. (2021) Sornekov et al. (2021) Sitore et al. (2021) Sitore et al. (2021) Sitore et al. (2021) Softeribaleur et al. (2021) Softeribaleur et al. (2021) Jakobsen et al. (2021) Jakobsen et al. (2021) Jakap et al. (2021) Aan et al. (2021) Aan et al. (2021) Softerist et al. (2022) Constantinus et al. (2021) Io et al. (2021) Io et al. (2021) Softist et al. (2022) Constantinus et al. (2021) Io et al. (2021) Softist et al. (2022) Softist et al. (2021) Softist et al. (2021)		Almodal et al. (2021) Almen et al 2021 Schwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $P = 93\%, r^2 = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2021) Bayart et al (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $P = 94\%, r^2 = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $P = 95\%, r^2 = 0.2303, p < 0.01$ Manufacturer = Lyher Scheiblauer et al. (2021) Manufacturer = Quidel Scheiblauer et al. (2021) Manufacturer = Quidel Scheiblauer et al. (2021)	~
Lopera et al. (2021) Caruana et al. (2021) Sorenkov et al (2021) Sorhenkov et al (2021) Sator et al. (2021) Sitoe et al. (2021) Sotebibauer et al. (2021) Sotebibauer et al. (2021) Sotebibauer et al. (2021) Dearo et al. (2021) Dearo et al. (2020) Dearo et al. (2020) Dearo et al. (2021) Diearo et al. (2021) Diearo et al. (2021) Diearo et al. (2021) TiND (2021) (an Honacker et al. (2021) Inot al. (2021) Sotifst et al. (2021) Sotifst et al. (2021) Sotifst et al. (2021) Soum et al. (2022) Down et al. (2022) Diearo et al. (2022) Diearo et al. (2022) Diearo et al. (2022) Diearo et al. (2022) Thommes et al. (2021) Soum et al. (2021) Soum et al. (2022) Diearo et al. (2021) Soum et al. (2021) S		Almona et al. (2021) Almen et al. (2021) Softwob et al. (2020) Chaimayo et al. (2020) Random effects model Heterogeneity: $\vec{r} = 93\%, \vec{r} = 0.6453, p < 0.01$ Manufacturer = Acon Pilecky et al. (2022) Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{r} = 94\%, \vec{r} = 0.4650, p < 0.01$ Manufacturer = Boson Scheiblauer et al. (2021) Bayart et al (2022) Random effects model Heterogeneity: $\vec{r} = 99\%, \vec{r} = 0.2303, p < 0.01$ Manufacturer = Lyher Scheiblauer et al. (2021) Manufacturer = Cuidel Scheiblauer et al. (2021) Heterogeneity: $\vec{r} = 92\%, \vec{r} = 0.6159, p < 0.01$ Test for subgroup differences: $\vec{x} = 46.20, df = 9 (p < 0.01)$	

Supplemental Figure 2: Overall RAT sensitivity across all studies included in the meta-analysis.

413

414





⁴¹⁸ asymptomatic cases coded by color.

419



420

421 Supplemental Figure 4: Sensitivity across studies for different RAT manufacturers with number of days

422 post symptom onset (DPSO: ≤5, ≤7, >7) coded by color.

^{427 (}Ct) value (≤20, ≤25, ≤30, ≤33) coded by color.

Study		Study					
Manufacturer = Abbott		Manufacturer = $SDB/Boche (cont'd)$					
Pilecky et al. (2022)		lääskeläinen et al. (2021)					- 5
Sitoe et al. (2022)		Alabounaim at al. (2021)					
		Alghounaim et al. (2021)					
Corman et al. (2021)		Homza et al. (2021)					
Jaaskelainen et al. (2021)		Corman et al. (2021)					-
Van Honacker et al. (2021) validation		Navero-Castillejos et al. (2022)					
Corman et al. (2021)	-8	Kruger et al. (2021)					+
Navero-Castillejos et al. (2022)	-3	Lindner et al. (2021)					
Konstantinus et al. (2021)	-5	Thell et al. (2021)					
Baro et al. (2021)		Turcato et al. (2021)					
Envresse et al (2021)		Lindhor et al. (2021)					
	-						
Olearo et al. (2020)	-8	Nikolai et al. (2021)					
Jeewandara et al. (2022)	•	Flinck et al. (2021)					
Peto (2021)	0	Kruger et al. (2020)					+
Schwob et al. (2020)	3	FIND (2021)					-
HSE COVID19 Antigen Testing Working Group (2021)	-	FIND (2021)					
Pérez-García et al. (2021)	3	Konstantinus et al. (2021)					
Caruana et al. (2021)		FIND (2021)					
Fourati et al. (2021)		END (2021)					
		FIND (2021)					
		FIND (2020)					6
Berger et al. (2021)	1	Ristič et al. (2021)					
Wertenauer et al. (2022)		Oh et al. (2021)					
Venekamp et al. (2021)		Salvagno et al. (2020)					
Venekamp et al. (2021)	1	Mockel et al. (2021)					5
Random effects model	<	Schuit et al. (2021)					
Heterogeneity: $l^2 = 88\%$ $t^2 = 4.7765$ $p < 0.01$		Favresse et al (2021)					
1000 genory, r = 0070, r = 4.1100, p < 0.01		Nikolai at al. (2021)					
Manufacturer Clamona							
manutacturer = Siemens	_	Nikolai et al. (2021)					
Nora et al. (2022)	-8	Igloi et al. (2021)					
Baro et al. (2021)		Jakobsen et al. (2021)					E
Navero-Castillejos et al. (2022)	-9	Park et al. (2022)					E
Pilecky et al. (2022)	-3	Olearo et al. (2020)					
Olearo et al. (2020)	-	Lindner et al. (2021)					
Bandom effects model	_						- 3
	·	Lee et al. (2022)					
Heterogeneity: $\Gamma = 0\%$, $T = 0$, $p = 1.00$		Lee et al. (2022)					- 1
		Randriamahazo et al (2021)					-1
Manufacturer = BD		Agarwal et al. (2021)					+
Kawser et al. (2021)	5 C	Jo et al. (2021)					- 2
Schuit et al. (2021)	8	Holzner et al. (2021)					
Caruana et al. (2021)		FIND (2021)					
Venekamp et al. (2021)		Idoi et al. (2021)					
Stohr at al 0001		lindner et el. (0001)					
Pandam offects model		Cursta et al. (2021)					
Random enects model	I	Gupta et al. (2020)					
Heterogeneity: $I^{-} = 0\%$, $T^{-} = 0$, $p = 0.64$		HSE COVID19 Antigen Testing Working Group (2021)	1				
		Nóra et al. (2022)					-
Manufacturer = Blosynex		Peña et al. (2021)					D
Van Honacker et al. (2021) validation		Lopera et al. (2021)					
HSE COVID19 Antigen Testing Working Group (2021)	3	Poopalasingam et al. (2022)					
Fourati et al. (2021)	8	Fernandez-Montero et al. (2021)					
Random effects model		Wertenauer et al. (2022)					
Haterogeneity $l^2 = 0\% r^2$ 75.0710 p. 1.00		Ven Llangeker et al. (2022)					
Heterogeneity: $\Gamma = 0\%$, $\tau = 75.0719$, $p = 1.00$		van Honacker et al. (2021) Implementation					
		FIND (2020)					•
Manufacturer = SDB/Roche		Berger et al. (2021)					+
Abdul-Mumin et al. (2021)		Mungomklang et al. (2021)					+
Koeleman et al. (2021)		Stohr et al 2021					E C
Paap et al. (2021)		Mockel et al. (2021)					
Pilecky et al. (2022)		Kawser et al. (2021)					
Nalumansi et al. (2020)		Caruana et al (2021)					
Roum at al. (2020)		Cabuahatal (2021)					
Fourier of al. (2021)	-						
Fourati et al. (2021)		Cerutti et al. (2021)					
Begum et al. (2021)		Venekamp et al. (2021)					
Kruttgen et al. (2021)	-8	Venekamp et al. (2021)					
Kim et al. (2021)		Zobrist et al. (2022)					
Baro et al. (2021)		Peña- Bodríguez et al. (2021)					
Begum et al. (2021)	-	Lee et al. (2021)					
Corman et al. (2021)		Octorman et al (2021)					
Dérez Cerele et el. (2021)		Usierman et al (2021)					
Perez-Garcia et al. (2021)		Jegerienner et al. (2021)					
FIND (2021)		Korenkov et.al (2021)					
Pandey et al. (2021)		Peto (2021)					
Jeewandara et al. (2022)	0	Rahman et al. (2021)					
Sitoe et al. (2022)	+	Akashi et al. (2022)					
FIND (2020)	-	Paap et al. (2021)					
Osterman et al. (2021)	-	Abnen et al 2021					
Usicinal et al. (2021)							
Labriarot et al. (2022)	-	Mori et al. (2022)					E
Labhardt et al. (2022)		Layer et al. (2022)					E
Kohmer et al. (2021)		Jakobsen et al (2021)					
Caruana et al. (2021)	-	Random effects model					
Nikolai et al. (2021)		Heterogeneity: $l^2 = 88\% = \frac{2}{1} = 2.4514$, $p < 0.01$					
Chaimavo et al. (2020)		1000000000000000000000000000000000000					
Konstantinus et al. (2020)		Menufacturer - Acon					
Konstantinus et al. (2021)							_
van Honacker et al. (2021) validation	-3	Pliecky et al. (2022)					
		Heterogeneity: $I^{c} = 89\%$, $\tau^{c} = 3.0068$, $p < 0.01$					
		Test for subgroup differences: $\chi_5^2 = 9.75$, df = 5 (p = 0.08)		T			
		-					
	0 20 40 60 80 100		0 2	20	40	00	ou 10

Supplemental Fig. 7: Specificity across studies for different RAT manufacturers with sample type

435 **REFERENCES**

436	1.	Wang, D., et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel
437		Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 2020. 323 (11): p. 1061-1069.
438	2.	Gradishar, W.J., et al., Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in
439		<i>Oncology.</i> J Natl Compr Canc Netw, 2022. 20 (6): p. 691-722.
440	3.	Centers for Disease Control and Prevention (CDC). Symptoms of COVID-19. Published 2021.
441		https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed
442		April 2023.
443	4.	World Health Organization (WHO). Coronavirus disease (COVID-19).
444		https://www.who.int/health-topics/coronavirus Accessed August 2023.
445	5.	Wolff, A.C., et al., Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer:
446		American Society of Clinical Oncology/College of American Pathologists Clinical Practice
447		<i>Guideline Focused Update.</i> J Clin Oncol. 2018. 36 (20): p. 2105-2122.
448	6.	Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality
449		worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. 68 (6): p. 394-424.
450	7.	Islam, F., et al., Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: Mutational
451		impacts, concerns, and the possible solutions. Ann Med Surg (Lond), 2022, 78 : p. 103737.
452	8	National Comprehensive Cancer Network NCCN Guidelines Version 2 2019 Breast Cancer 2019
453		[cited 2019 Aug. 27]: Available from:
454		https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
455	9.	Ferlay, J., et al. Global Cancer Observatory: Cancer Today Breast Cancer Fact Sheet, 2018 [cited]
456		2019 Aug. 261: Available from: https://gco.jarc.fr/today/fact-sheets-cancers
457	10	Brummer F et al. Accuracy of novel antigen ranid diagnostics for SARS-CoV-2: A living
458		systematic review and meta-analysis. PLoS Med. 2021. 18 (8): p. e1003735.
459	11.	Dinnes, J., et al., Rapid, point-of-care antiaen and molecular-based tests for diagnosis of SARS-
460		<i>CoV-2 infection</i> . Cochrane Database Syst Rev. 2021. 3 (3): p. CD013705.
461	12	Corman V M et al. Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen
462		tests: a single-centre laboratory evaluation study. Lancet Microbe 2021 $2(7)$: p. e311-e319
463	13.	Page, M.J., et al., The PRISMA 2020 statement: an updated guideline for reporting systematic
464		<i>reviews</i> . BMJ. 2021. 372 : p. n71.
465	14.	Whiting, P., et al., The development of OUADAS: a tool for the quality assessment of studies of
466		diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003. 3 : p. 25.
467	15.	Schwarzer G. 2020. Meta (version 4.15-1) [program]https://CRAN.R-project.org/package=meta
468		[Accessed 29 December 2022].
469	16.	Reitsma JB. Glas AS. Ruties AW. Scholten RJ. Bossuvt PM. Zwinderman AH. Bivariate analysis of
470		sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin
471		Epidemiol. 2005;58(10);982-990. doi:10.1016/i.iclinepi.2005.02.022
472	17.	Doebler P. 2017. Mada (version 0.5.8) [program]https://CRAN.R-project.org/package=mada
473		[Accessed 29 December 2022].
474	18.	Rutter, C.M. and C.A. Gatsonis, A hierarchical regression approach to meta-analysis of
475		diaanostic test accuracy evaluations. Stat Med. 2001. 20 (19): p. 2865-84.
476	19.	legerlehner, S., et al., Diggnostic accuracy of a SARS-CoV-2 rapid antigen test in real-life clinical
477		<i>settings</i> . Int J Infect Dis. 2021. 109 : p. 118-122.
478	20.	Jakobsen KK, Jensen JS, Todsen T, Lippert F. Martel CJ. Klokker M. von Buchwald C. Detection of
479		SARS-CoV-2 infection by rapid antiaen test in comparison with RT-PCR in a public setting.
480		MedRxiv. 2021 Jan 25:2021-01.

481	21.	European Commission (EC) for the European Union (EU). Commission Implementing Regulation
482		(EU) 2022/1107 of 4 July 2022 laying down common specifications in accordance with
483		Regulation (EU) 2017/746. https://health.ec.europa.eu/latest-updates/commission-
484		implementing-regulation-eu-20221107-4-july-2022-laying-down-common-specifications-2022-
485		07-05_en Accessed June 2023.
486	22.	European Centre for Disease Prevention and Control (ECDC). Options for the use of rapid
487		antigen tests for COVID-19 first update, October 2021.
488		https://www.ecdc.europa.eu/sites/default/files/documents/Options-for-the-use-of-rapid-
489		antigen-tests-for-COVID-19-first-update.pdf Accessed May 2023.
490	23.	Sung, H., et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
491		Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71 (3): p. 209-249.
492	24.	Lee, L.Y.W., et al., Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity by
493		Viral Load, S Gene Variants and Demographic Factors, and the Utility of Lateral Flow Devices to
494		Prevent Transmission. Clin Infect Dis, 2022. 74 (3): p. 407-415.
495	25.	Zhou, J., et al., Viral emissions into the air and environment after SARS-CoV-2 human challenge:
496		a phase 1, open label, first-in-human study. Lancet Microbe, 2023.
497	26.	van Beek, J., et al., From more testing to smart testing: data-guided SARS-CoV-2 testing choices,
498		the Netherlands, May to September 2020. Euro Surveill, 2022. 27 (8).
499	27.	Lavezzo, E., et al., Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'.
500		Nature, 2020. 584 (7821): p. 425-429.
501	28.	Arons, M.M., et al., Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled
502		Nursing Facility. N Engl J Med, 2020. 382 (22): p. 2081-2090.
503	29.	Kritikos, A., et al., Sensitivity of Rapid Antigen Testing and RT-PCR Performed on
504		Nasopharyngeal Swabs versus Saliva Samples in COVID-19 Hospitalized Patients: Results of a
505		Prospective Comparative Trial (RESTART). Microorganisms, 2021. 9(9).
506		